Skip to content

Early menstrual induction - Proof of concept study

Early Menstrual Induction (EMI): A proof of concept study on a post-fertilization fertility regulation method with a combination of levonorgestrel and mifepristone

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18799324
Enrollment
80
Registered
2021-08-03
Start date
2021-09-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To prevent an intrauterine pregnancy in women who have had unprotected intercourse and missed the emergency contraception window Pregnancy and Childbirth

Interventions

1. Blood is drawn from women who meet the inclusion criteria to measure plasma ßhCG. If the value is >10 mIU/ml the women are included in the study. If lower than 10 mIU/ml, the women are requested to

Sponsors

Concept Foundation
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women aged 18 - 45 years 2. Regular menstrual cycles (duration of 25 – 35 days) 3. Intend to end the pregnancy if confirmed 4. Unprotected intercourse > 5 days but before expected menstruation 5. Positive plasma ßhCG (>10 mIU/ml) 6. Agree not to use any other contraception method during the study period 7. Literacy to read and understand the study procedures

Exclusion criteria

Exclusion criteria: 1. Irregular menstrual cycles 2. Breastfeeding 3. Unknown date of last menstrual period 4. Use of emergency contraception during the current menstrual cycle 5. Known allergy or any contraindication to levonorgestrel or mifepristone 6. Any systemic illness that requires the use of regular medications or any other serious medical disease 7. Any cases where the woman indicates pregnancy caused by rape, as the woman may need additional support and care. These women will be referred for appropriate services, including for termination of pregnancy where desired.

Design outcomes

Primary

MeasureTime frame
Effect of the intervention measured by plasma ßhCG on Day 14

Secondary

MeasureTime frame
1. Amount of uterine bleeding after treatment measured using a self-recording questionnaire for day 1-2, and day 3-14 2. Length of post-treatment menstrual cycle measured using a self-recording questionnaire for day 1-2, and day 3-14 3. Satisfaction using the intervention measured using a self-recording questionnaire for day 3-14 4. Side-effects of drugs measured using a self-recording questionnaire for day 1-2, and day 3-14

Countries

Thailand

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026